Umer Raffat is a Senior Managing Director at Evercore ISI and heads our large cap therapeutics effort spanning Biotech, Pharmaceuticals-major and Specialty Pharmaceuticals.
Umer has been ranked #1 on five separate occasions by Institutional Investor, including in 2015 – his first year covering the sector. In 2017, Institutional Investor ranked him as #1 in Biotech and Specialty Pharmaceuticals categories. Previously, he ranked #1 Rising Star Analyst two years in a row – once in Specialty Pharma and once in Biotech.
Mr. Raffat started his equity research career covering Biotech for 5 years under #1 ranked Dr. Mark Schoenebaum. Mr. Raffat and Dr. Schoenebaum moved to Evercore ISI from Deutsche Bank in 2010. Mr. Raffat has an undergrad in biology from University of Texas at Arlington and a Masters from Harvard School of Public Health.